Literature DB >> 28967370

Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain.

Rachel E Miller1, Anne-Marie Malfait1, Joel A Block2.   

Abstract

Blockade of nerve growth factor (NGF) with antibodies is a promising strategy for treatment of chronic pain associated with osteoarthritis (OA). This narrative review describes the current status of NGF-blockade for the treatment of OA pain. We summarise briefly current evidence for the efficacy and risks of anti-NGF blockade. Two anti-NGF antibodies, tanuzemab and fasinumab, are in active development, with tanuzemabclose to completing Phase 3 trials in preparation for an application for approval for clinical use.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28967370      PMCID： PMC6007861     

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN： 0392-856X            Impact factor:   4.473


  21 in total

1.  Rita Levi-Montalcini: the discovery of nerve growth factor and modern neurobiology.

Authors:  Luigi Aloe
Journal:  Trends Cell Biol       Date:  2004-07       Impact factor: 20.808

2.  Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies.

Authors:  M C Hochberg
Journal:  Osteoarthritis Cartilage       Date:  2015-01       Impact factor: 6.576

3.  Osteoarthritis in 2016: Anti-NGF treatments for pain - two steps forward, one step back?

Authors:  Nancy E Lane; Maripat Corr
Journal:  Nat Rev Rheumatol       Date:  2017-01-25       Impact factor: 20.543

4.  Antagonism of nerve growth factor-TrkA signaling and the relief of pain.

Authors:  Patrick W Mantyh; Martin Koltzenburg; Lorne M Mendell; Leslie Tive; David L Shelton
Journal:  Anesthesiology       Date:  2011-07       Impact factor: 7.892

Review 5.  A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee.

Authors:  T J Schnitzer; J A Marks
Journal:  Osteoarthritis Cartilage       Date:  2015-01       Impact factor: 6.576

Review 6.  Tanezumab in the treatment of chronic musculoskeletal conditions.

Authors:  Prakash Jayabalan; Thomas J Schnitzer
Journal:  Expert Opin Biol Ther       Date:  2016-12-25       Impact factor: 4.388

7.  Tanezumab for the treatment of pain from osteoarthritis of the knee.

Authors:  Nancy E Lane; Thomas J Schnitzer; Charles A Birbara; Masoud Mokhtarani; David L Shelton; Mike D Smith; Mark T Brown
Journal:  N Engl J Med       Date:  2010-09-29       Impact factor: 91.245

Review 8.  Towards a mechanism-based approach to pain management in osteoarthritis.

Authors:  Anne-Marie Malfait; Thomas J Schnitzer
Journal:  Nat Rev Rheumatol       Date:  2013-09-17       Impact factor: 20.543

Review 9.  Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?

Authors:  Rachel E Miller; Joel A Block; Anne-Marie Malfait
Journal:  Curr Opin Rheumatol       Date:  2017-01       Impact factor: 5.006

10.  When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program.

Authors:  Marc C Hochberg; Leslie A Tive; Steven B Abramson; Eric Vignon; Kenneth M Verburg; Christine R West; Michael D Smith; David S Hungerford
Journal:  Arthritis Rheumatol       Date:  2016-02       Impact factor: 10.995
View more
  16 in total

1.  Overlapping features of rapidly progressive osteoarthrosis and Charcot arthropathy.

Authors:  Takashi Sono; Carolyn A Meyers; Daniel Miller; Catherine Ding; Edward F McCarthy; Aaron W James
Journal:  J Orthop       Date:  2019-03-12

2.  A prospective observational study on the long-term results of 90Yttrium citrate radiosynoviorthesis of synovitis in osteoarthritis of the knee joint.

Authors:  Margit Szentesi; Zoltán Nagy; Pal Géher; István Papp; Willm Uwe Kampen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-05-25       Impact factor: 9.236

3.  Angiotensin II Triggers Peripheral Macrophage-to-Sensory Neuron Redox Crosstalk to Elicit Pain.

Authors:  Andrew J Shepherd; Bryan A Copits; Aaron D Mickle; Páll Karlsson; Suraj Kadunganattil; Simon Haroutounian; Satya M Tadinada; Annette D de Kloet; Manouela V Valtcheva; Lisa A McIlvried; Tayler D Sheahan; Sanjay Jain; Pradipta R Ray; Yuriy M Usachev; Gregory Dussor; Eric G Krause; Theodore J Price; Robert W Gereau; Durga P Mohapatra
Journal:  J Neurosci       Date:  2018-07-05       Impact factor: 6.167

4.  Systemic L-Buthionine -S-R-Sulfoximine Treatment Increases Plasma NGF and Upregulates L-cys/L-cys2 Transporter and γ-Glutamylcysteine Ligase mRNAs Through the NGF/TrkA/Akt/Nrf2 Pathway in the Striatum.

Authors:  Cesar Valdovinos-Flores; Jorge H Limón-Pacheco; Renato León-Rodríguez; Pavel Petrosyan; Carla Garza-Lombó; Maria E Gonsebatt
Journal:  Front Cell Neurosci       Date:  2019-07-23       Impact factor: 5.505

5.  Spinal Mobilization Prevents NGF-Induced Trunk Mechanical Hyperalgesia and Attenuates Expression of CGRP.

Authors:  William R Reed; Joshua W Little; Carla R Lima; Robert E Sorge; Ceren Yarar-Fisher; Mualla Eraslan; Christopher P Hurt; Timothy J Ness; Jianguo G Gu; Daniel F Martins; Peng Li
Journal:  Front Neurosci       Date:  2020-04-30       Impact factor: 4.677

6.  The Efficacy, Tolerability, and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Authors:  Paula Dakin; Stephen J DiMartino; Haitao Gao; Jennifer Maloney; Alan J Kivitz; Thomas J Schnitzer; Neil Stahl; George D Yancopoulos; Gregory P Geba
Journal:  Arthritis Rheumatol       Date:  2019-09-20       Impact factor: 10.995

Review 7.  Understanding the genetic basis of congenital insensitivity to pain.

Authors:  Ichrak Drissi; William Aidan Woods; Christopher Geoffrey Woods
Journal:  Br Med Bull       Date:  2020-05-15       Impact factor: 4.291

Review 8.  Understanding the Molecular Mechanisms Underlying the Pathogenesis of Arthritis Pain Using Animal Models.

Authors:  Jeong-Im Hong; In Young Park; Hyun Ah Kim
Journal:  Int J Mol Sci       Date:  2020-01-14       Impact factor: 5.923

Review 9.  Recent advances in the treatment of osteoarthritis.

Authors:  Susanne Grässel; Dominique Muschter
Journal:  F1000Res       Date:  2020-05-04

10.  Proteomic Analysis of Uterine Tissues During Peri-Implantation Period in Mice with Experimentally Induced Adenomyosis that Treated with anti-Ngf: Implications for Cell-Cell Adhesion and Metabolic Processes.

Authors:  Yan Li; Dan Zhang; Bailing Jin; Lan Xia; Aijun Zhang
Journal:  Reprod Sci       Date:  2020-07-16       Impact factor: 3.060
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.